where experts go to learn about the FDA
FDA Law Blog where experts go to learn about FDA
Hyman, Phelps & McNamara, P.C.
Menu
Menu
  • Practices
  • Industries
  • FDA Regulatory Categories
  • Professionals
  • About Us
  • Contact
  • LinkedIn
  • Twitter
FDA Law Blog
News & Events
  • LinkedIn
  • Twitter
  • Recent Posts
    • Here’s Looking at You, OTC Drugs: FDA Requests Information to Plan for Public Meeting on Increasing Access to Nonprescription Drugs and Issues New MaPP on OTC Switches and Generics December 11, 2025
    • When is an Approval Not an Approval? Before 1962. December 10, 2025
    • Don’t Miss Today’s Medical Device Webinar December 10, 2025
    • You Better Move Fast: ACCESS to TEMPO December 8, 2025
    • FDA’s Tobacco Civil Money Penalty Authority, cont’d: Not Backing Down December 3, 2025
  • Trackers
    • 180-Day Exclusivity Tracker
    • FDA Citizen Petition Tracker
    • REMS Tracker (Historical – Not Recently Updated)
    • FDA Legislation Tracker
  • Orange Book Archives

     

    ANDA Paragraph IV Patent Certifications List Archives

  • Scorecards
    • Generic Drug Labeling Carve-Out Scorecard
    • Biosimilars State Legislation Scorecard (Historical – Not Recently Updated) 
  • Blogroll
    • Big Molecule Watch Blog
    • Bloomberg BNA Health Care Blog
    • Drug and Device Law Blog
    • Eye on FDA
    • FDA Matters
    • Harvard Law Bill of Health
    • IN VIVO Blog
    • Internet Drug News.com
    • Lachman Consultants Blog
    • Medical Devices Today
    • Orange Book Blog
    • The Orange Book Insights Blog
    • Pharma IQ
    • Pharmalot
    • SCOTUS Blog
    • The Volokh Conspiracy
    • WLF Legal Pulse
  • Resources
    • Centers for Medicare & Medicaid Services
    • Drug Enforcement Administration
    • Food and Drug Administration
  • Categories
    • Advertising and Promotion (Federal Trade Commission)
    • Advertising and Promotion (OPDP)
    • Animal Drugs and Feeds
    • Biosimilars
    • Cannabis
    • cGMP Compliance
    • Consumer Product Safety Commission
    • Controlled Substances
    • Cosmetics
    • COVID19
    • Current Affairs
    • Dietary Supplements
    • Drug Development
    • Drug Enforcement Administration
    • Enforcement
    • FDA News
    • Foods
    • Foods and Dietary Supplements
    • Fraud and Abuse
    • Government Pricing
    • Hatch-Waxman
    • Health Care
    • Health Privacy
    • Import/Export
    • In Vitro Diagnostic Devices
    • Jobs
    • Medical Devices
    • Miscellaneous
    • Orphan Drugs
    • OTC Drugs and Cosmetics
    • Prescription Drugs and Biologics
    • Product Jurisdiction and Combination Products
    • Reimbursement
    • Tissue Products
    • Tobacco
    • Uncategorized
  • Your search for “Reliable HL7-FHIR Dumps - HL7 HL7 FHIR STU3 Proficiency Realistic Reliable Dumps Pass Guaranteed 💦 Open website ➠ www.pdfvce.com 🠰 and search for ➥ HL7-FHIR 🡄 for free download 🧐HL7-FHIR Reliable Test Labs” returned the following results.

    HP&M Weighs in on FDA’s “Technical Assistance” to Proposed IVD Legislation

    …test developers must use test platforms that comply with the Act. Again, what it will mean to comply is unclear. If the intention is that the current exemption for test…

    The End* of a Long and Winding Road: FDA Publishes Final LDT Rule (*Or Is It?)

    …801 and 809)   Labs conducting LDTs for clinical investigations must comply with applicable investigational device requirements (e.g., 21 C.F.R. Part 812)   Stage 3 May 6, 2027 Compliance with…

    Court Finds That Lane Labs’ Advertising Claim Lacks Substantiation

    …the parties in 2000.  In part, that order requires Lane Labs’ health-related marketing claims to be substantiated by competent and reliable scientific evidence.  The district court found that Lane Labs’…

    MedTech Conference Download

    At the latest MedTech conference held in Boston, MA from October 24-26, we heard from FDA officials and industry representatives on a range of topics. Below, we provide a snapshot…

    District Court Decides that Garden of Life’s Expert Opinion Constitutes Competent and Reliable Evidence

    …competent and reliable evidence does not mean “uncontroverted proof” and denied the FTC’s motion. Whether this decision means that FTC may need to reconsider what constitutes “competent and reliable” scientific…

    The Clot Thickens! Bloggers Beware! Congress Requests Information from Drug Rep. Website on Anonymous Postings Concerning Early ENHANCE Study Results

    …Commerce Committee Oversight and Investigations Subcommittee sent a letter to the operators of the website Cafepharma.com (a self-proclaimed “site for drug reps by drug reps”) requesting information on anonymous postings…

    Disclosures in a Small Space: The FTC’s Revisions to .Com Disclosures

    Somewhat later than anticipated, the Federal Trade Commission (“FTC”) has published a revised version of its guide, .Com Disclosures.  The FTC released the original guide 13 years ago, when mobile phones…

    Molecular Pathologist Group Proposes Legislative Solution to Modernize CLIA, Including CMS/Third-Party Premarket Review, as Substitute for FDA’s LDT Framework

    …LDPs would use a methodology that “lends itself to inter-laboratory comparisons or proficiency testing.”  Low-risk tests, by contrast, would either be adjunctive in nature or protocols for which “the consequence…

    FDA Issues Final Rule and Guidance on Electronic MDR Reporting

    …Safety Reports (HL7 ICSR) for submission of batch reports (high volume reporting).  Id. at 8834.  The eSubmitter software can be downloaded for free from FDA’s website.  The software generates an…

    FTC Loses Again; Court of Appeals Affirms Lower Court’s Determination that Garden of Life’s Expert Opinion Constitutes Competent and Reliable Evidence

    …claims unless such claims are substantiated by competent and reliable scientific evidence.  The FTC alleged that certain advertising claims subsequently made by GOL were not supported by “competent and reliable…

    FDA’s IVD TA: It’s Not Just Technical Assistance

    …multifaceted term is created. A test group means tests that have the following common elements: 1) the substance measured, 2) the type of specimen, 3) the test method, 4) the…

    A Court’s Contempt for the Government in Bayer

    …– undoubtedly at significant expense to the company.  If this level of substantiation is viewed by the government in the future as a “floor” for “competent and reliable scientific evidence”…

    HHS OIG Issues Advisory Opinion Regarding Free Drugs

    …a one- to two-month supply of a drug cost-free where a new patient was experiencing reimbursement delays (see our blog post here). Another series of advisory opinions approved of free…

    Search Warrants – What Happens When the FDA Storm Arrives

    …collect evidence, catching unsuspecting companies by surprise. Given FDA’s increasing use of criminal search warrants, companies regulated by FDA should take precautionary steps to ensure that their business is prepared…

    FTC Could Revise its Dot Com Disclosures Guidelines by Fall 2012

    …There were a few presentations that included research and data on how consumers read disclosures online, and the innovative techniques that some companies are creating to effectively communicate disclosures (including…

    Page 2 of 114«123...1020...»Last »

    Search FDA Law Blog

    Subscribe

    Never miss a post from FDA Law Blog







    Latest Tweets

    Tweets by @fdalawblog

    Awards & Honors

    • Best Lawyers in America® – 2025
    • Ranked in Chambers USA – 2024
  • Recent Posts
    • Here’s Looking at You, OTC Drugs: FDA Requests Information to Plan for Public Meeting on Increasing Access to Nonprescription Drugs and Issues New MaPP on OTC Switches and Generics December 11, 2025
    • When is an Approval Not an Approval? Before 1962. December 10, 2025
    • Don’t Miss Today’s Medical Device Webinar December 10, 2025
    • You Better Move Fast: ACCESS to TEMPO December 8, 2025
    • FDA’s Tobacco Civil Money Penalty Authority, cont’d: Not Backing Down December 3, 2025
  • Trackers
    • 180-Day Exclusivity Tracker
    • FDA Citizen Petition Tracker
    • REMS Tracker (Historical – Not Recently Updated)
    • FDA Legislation Tracker
  • Orange Book Archives

     

    ANDA Paragraph IV Patent Certifications List Archives

  • Scorecards
    • Generic Drug Labeling Carve-Out Scorecard
    • Biosimilars State Legislation Scorecard (Historical – Not Recently Updated) 
  • Blogroll
    • Big Molecule Watch Blog
    • Bloomberg BNA Health Care Blog
    • Drug and Device Law Blog
    • Eye on FDA
    • FDA Matters
    • Harvard Law Bill of Health
    • IN VIVO Blog
    • Internet Drug News.com
    • Lachman Consultants Blog
    • Medical Devices Today
    • Orange Book Blog
    • The Orange Book Insights Blog
    • Pharma IQ
    • Pharmalot
    • SCOTUS Blog
    • The Volokh Conspiracy
    • WLF Legal Pulse
  • Resources
    • Centers for Medicare & Medicaid Services
    • Drug Enforcement Administration
    • Food and Drug Administration
  • Categories
    • Advertising and Promotion (Federal Trade Commission)
    • Advertising and Promotion (OPDP)
    • Animal Drugs and Feeds
    • Biosimilars
    • Cannabis
    • cGMP Compliance
    • Consumer Product Safety Commission
    • Controlled Substances
    • Cosmetics
    • COVID19
    • Current Affairs
    • Dietary Supplements
    • Drug Development
    • Drug Enforcement Administration
    • Enforcement
    • FDA News
    • Foods
    • Foods and Dietary Supplements
    • Fraud and Abuse
    • Government Pricing
    • Hatch-Waxman
    • Health Care
    • Health Privacy
    • Import/Export
    • In Vitro Diagnostic Devices
    • Jobs
    • Medical Devices
    • Miscellaneous
    • Orphan Drugs
    • OTC Drugs and Cosmetics
    • Prescription Drugs and Biologics
    • Product Jurisdiction and Combination Products
    • Reimbursement
    • Tissue Products
    • Tobacco
    • Uncategorized
  • Copyright 2025 FDA Law Blog HPM
    • Disclaimer
    • Careers